GenScript is a global biotechnology group. GenScript’s businesses encompass four major categories based on its leading gene synthesis technology, including operation as a Life Science CRO, enzyme and synthetic biology products, biologics development and manufacturing, as well as cell therapy.
Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific. Today, over 300,000 customers from over 160 countries and regions around the world have used GenScript’s premier, convenient, and reliable products and services.
GenScript currently has more than 3000 employees globally, 33% of whom hold master’s and/or Ph.D. degrees. In addition, GenScript has a number of leading commercial technologies developed in the fields of synthetic biology, immunotherapy, antibody design, chemical synthesis and bioinformatics, including more than 70 patents and over 200 patent applications. As of January 2019, GenScript's products and services have been cited by 36,500 scientific papers worldwide.
GenScript is committed to striving towards its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology.
For more information, visit www.genscript.com
Pall Corporation provides critical filtration, separation, and purification solutions to meet the demanding needs of a broad spectrum of life sciences and industrial customers around the globe. Across 80 locations and 10,000 people worldwide, we are unified by a singular drive: to solve our customers' biggest fluid management challenges. And in doing so advance health, safety, and environmentally responsible technologies. Together, our Life Sciences and Industrial teams serve a diverse range of customers including biotechnology, pharmaceutical, medical, food and beverage, laboratory, microelectronics, aerospace, fuels, petrochemical, chemical, automotive and power generation industries. Our industry-leading technologies and solutions are at work in countless applications, protecting critical operating assets, improving product quality, safeguarding the health, and minimizing emissions and waste
For more info, please check: https://www.pall.com/en/biotech.html
West Pharmaceutical Services, Inc. is a leading manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. Working by the side of its customers from concept to patient, West creates products that promote the efficiency, reliability, and safety of the world's pharmaceutical drug supply. West is headquartered in Exton, Pennsylvania, and supports its customers from locations in North and South America, Europe, Asia, and Australia. West's 2019 net sales of $1.84 billion reflect the daily use of approximately 100 million of its components and devices, which are designed to improve the delivery of healthcare to patients around the world.
TECHNOLOGY SHOWCASE SPONSOR
Retrogenix, a Charles River Company provides a fast, accurate, and effective solution for primary receptor identification and specificity screening of antibodies, protein ligands, CAR T cells, and other biotherapeutics. Biologically relevant targets are identified by screening for interactions against the most comprehensive set of the plasma membrane and tethered secreted proteins that are expressed in
human cells. This informs lead selection, assists with safety assessment, and has generated data that has been used in patent applications and NDA submissions to both the US FDA and EMA.
For more details of our technology see our website animation at: www.retrogenix.com/the-technology/
Astrea Bioseparations Ltd. (formerly Prometic Bioseparations Ltd) provides bioseparation products to the pharmaceutical and biotech markets, including chromatography adsorbents, custom adsorbent discovery and development services and pre-packed chromatography columns and column hardware.
Astrea Bioseparations is focused on purity and precision as we support customers working to Discover. Develop. and Deliver. quality products to the market that treat or potentially cure diseases. At Astrea Bioseparations every detail matters as our team works to create tailored solutions that streamline processes from early clinical to commercial phases.
A wholly-owned subsidiary of Gamma Biosciences, a life sciences tools platform supported by KKR, Astrea Bioseparations has R&D laboratories located at Cambridge, UK and manufacturing facilities located at the Isle of Man, British Isles, Joliette, Quebec, Canada and Stoughton, Massachusetts, USA.
For more information, please visit: https://www.astreabioseparations.com/
Lumis International GmbH was founded in 2013 with the goal to act as a bridge to Europe for clinical research activities. The company is specialized in providing legal representation services and regulatory consulting for biopharmaceutical and medical device companies who intend to develop their product in the European market but are located in non-EU countries around the globe.
Lumis Life Science Consulting GmbH was founded in 2020 as an independent subsidiary of Lumis International to provide customer-tailored consulting and solutions for clinical vendor selection and management, clinical trial oversight, quality management, and training.
Novo Nordisk Pharmatech A/S is a global and leading manufacturer of pharmaceutical ingredients for the pharmaceutical and biopharmaceutical industries. The company specializes in Recombinant Insulin and cGMP manufactured quaternary ammonium compounds (Quats).
The mission is to enable better medicines by providing sustainable pharmaceutical materials through innovative and customized solutions. Novo Nordisk Pharmatech helps the world´s largest pharmaceutical and biopharmaceutical industries reducing their risk for raw materials by using pharma-grade products with a high level of consistency, purity, quality, and reliability.
Novo Nordisk Pharmatech´s high purity, non-therapeutic Insulin is sourced directly from parent company Novo Nordisk, the world’s largest insulin producer. Recombinant Insulin stimulates the proliferation of cells, enhances the yield, and is a key component in serum-free growth media for mammalian cells. It is used to manufacture monoclonal antibodies, virus vaccines, gene therapy products, and other biological drug products approved by regulatory bodies worldwide, including FDA and EMA.
Novo Nordisk Pharmatech manufactures Quats in an unequaled, full cGMP grade, ensuring exceptionally high purity and batch-to-batch consistency. Benzalkonium Chloride, Cetrimide, and Cetrimonium Bromide/CTAB) is suited for a wide range of pharmaceutical applications that require high purity and quality, such as vaccine production. And as preservatives (excipients) or APIs in many ophthalmic, nasal, oral, and topical drugs and in various solutions, ointments, gels, and creams.
More than 70 years of experience has provided the know-how to ensure maximum product purity and keeping impurities to even lower levels than pharmacopeial standards. This has made the company a leading global supplier of high-quality ingredients - enabling the customers to make even better medicines.
Taiwan Bio Industry Organization (TBIO) established in 1989, is the largest and the most influential biotechnology organization in Taiwan. TBIO represents over 300 members ranging from private companies and academic institutes to government bodies involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology. We are a strong arm to foster the development of biotechnology in Taiwan. Our mission is to provide advocacy, business development, industrial training and communication service for our members.
TBIO organizes regular conferences and meetings inviting key industry leaders and government representatives to address members’ interests and concerns. From 2019, TBIO partners with BIO to cohost its annual event under the new name of BIO Asia–Taiwan. Now BIO Asia–Taiwan is Asia's largest biotech partnering and networking event, attracting and engaging thousands of global biotech leaders, innovators, and investors each year.